CompletedPhase 4

Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension

South Korea80 participantsStarted 2017-09-11

Plain-language summary

This study is to evaluate effect and safety on central blood pressure with Duowell compared to telmisartan monotherapy in mild dyslipidemia patients with hypertension during 16 weeks.

Who can participate

Age range40 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. CPK ≥ 3 times the normal upper limit
✕. Serum Creatinine \> 3 mg/dL
✕. Serum Potassium \> 5.5 mmol/L
✕. ALT or AST ≥ 3 times the upper normal limit

What they're measuring

Changes from baseline in mean central systolic blood pressure

Timeframe: at week 16

Trial details

NCT IDNCT03267329

SponsorYuhan Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-09-02

View on ClinicalTrials.gov More Hypertension trials